Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLZ-100 in skin cancer
NCT02097875Phase 1Completed
- Sponsor
- Blaze Bioscience
- Start
- Dec 2013
- Primary completion
- Mar 2015
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tozuleristide in skin cancer, sponsored by Blaze Bioscience. Primary endpoint: Number of participants with adverse events at 1 week. Started Dec 2013; status: completed.
02
Drugs
tozuleristide
03
Conditions
skin cancer
Beyond the preview
Go deeper on NCT02097875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097875.